This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Enzon Announces The Initiation Of Two Phase I Studies In Collaboration With The National Cancer Institute

The EZN-2208 study is expected to enroll 20 patients with solid tumors whose disease has progressed following standard therapy, or who have no acceptable standard treatment. EZN-2208 will be administered intravenously on days one, eight, and fifteen of a 28-day cycle. Avastin will be administered intravenously every two weeks. Tumor biopsies and other correlative imaging and pharmacodynamic studies will be performed at baseline and after drug administration.

About EZN-2968 (HIF-1a mRNA antagonist)

EZN-2968 is an antisense oligodeoxynucleotide that down regulates the mRNA encoding HIF-1α. The molecule is based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S. The LNA technology allows the antisense molecule to have high-potency resistance to nuclease destruction, and administration of the molecule intraveneously when prepared in saline (without any delivery vehicle). Reduction in HIF-1α expression would be expected to lead to inhibition of angiogenesis, the inhibition of tumor cell proliferation, and apoptosis. HIF-1α, normally activated in response to hypoxia-induced stress, is a key transcription regulator of a large number of genes important in cellular adaptation to low-oxygen conditions, including angiogenesis, cell proliferation, apoptosis, and cell invasion.

About EZN-2208 (PEG-SN38)

SN38 is the active metabolite of the widely used cancer drug irinotecan, marketed as Camptosar® in the U.S. Although unmodified SN38 is 1,000 times more potent than CPT-11, it has not been converted into a viable drug candidate because of its insolubility. Using Enzon's proprietary customized linker-enhanced PEGylation technology, the Company developed EZN-2208 (PEG-SN38), which results in a compound with excellent pharmaceutical properties as shown in animal models: increased solubility, higher exposure, and longer half-life than unmodified SN38. These properties allow EZN-2208 to outperform CPT-11 in a variety of animal models of human cancers, including tumors that develop resistance to CPT-11. EZN-2208 is currently being evaluated in ongoing Phase II clinical trials in patients with metastatic breast cancer and metastatic colorectal carcinoma, and in a Phase I study in pediatric patients with solid tumors.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.04 1.50%
FB $117.98 -0.50%
GOOG $695.45 -0.40%
TSLA $236.13 -2.30%
YHOO $36.08 -1.20%


Chart of I:DJI
DOW 17,741.68 -149.48 -0.84%
S&P 500 2,061.50 -19.93 -0.96%
NASDAQ 4,767.6290 -49.9650 -1.04%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs